All In Biotech

Drug Trial Radar · NCT07417735

SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma

A Randomized, Controlled, Open-Label, Multicenter Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of SYS6010 Versus Investigator's Choice Chemotherapy in Patients With Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma Who Have Failed at Least One Line of Systemic Therapy.

Last checked: Nov 19, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 436 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

436

Planned (sponsor's estimate)

Start

Mar 18, 2026

Primary completion

Dec 31, 2028

Study completion Dec 31, 2029

Sponsor

Sponsor type
Industry
First posted
Feb 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized, Controlled, Open-Label, Multicenter Phase Ⅲ Study of SYS6010 vs Investigator's Choice Single-Agent Chemotherapy in Locally Advanced/Metastatic/Recurrent ESCC Patients with Failure of At Least One Line of Systemic Therapy

Conditions

  • Locally Advanced/Metastatic/Recurrent ESCC

Interventions

  • SYS6010Drug

    SYS6010 IV

  • Investigator's Choice of Chemotherapy (Irinotecan hydrochloride,Paclitaxel,Docetaxel)Drug

    Investigator's choice of chemotherapy means the chemotherapy chosen by investigators/doctors to treat Locally Advanced/Metastatic/Recurrent ESCC, including Irinotecan hydrochloride(125 mg/m\^2 by IV on D1 and D8,3 weeks/cycle;or 150 \~180 mg/m\^2 by IV on D1,Q2W,4 weeks/cycle), Paclitaxel(175 mg/m\^2 by IV on D1,3 weeks/cycle;or 80 mg/m\^2 by IV on D1/D8/D15/D22,4 weeks/cycle;or 80 mg/m\^2 by IV on D1/D8/D15,4 weeks/cycle), or Docetaxel(75\~100 mg/m\^2 by IV on D1,3 weeks/cycle)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) Assessed by Blinded Independent Central Review(BICR) According to the RECIST 1.1 CriteriaTime frame: Up to 2 years
  2. Overall Survival (OS)Time frame: Up to 2 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.